Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Hormone therapy shifts body proteins to match gender identity

Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...

Targeting 'molecular bodyguards' weakens prostate cancer cells

Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...

Females found to carry a higher genetic risk of depression

An international team of scientists has discovered about twice as many genetic 'flags'...

Content from other channels on our network

Keeping Infection Prevention Front of Mind – Every Day of the Year

WA invests $1.5bn in three major new public hospital projects

Framework seeks to cut medicine errors at transitions of care

Nominations open for 2026 HESTA Australian Nursing & Midwifery Awards

Report explores Australian perceptions of Medtech access

Discovery improves silicon solar efficiency

Partnership to redefine thermal comfort index

Dashboard to support climate-aware business decisions

Australia's homes aren’t ready for the heat — here's how to fix them

Program assists power station workers to find new careers

Roma Foods celebrates over 70 years of Australian manufacturing

Rock lobster exporter improves supply chain efficiency

Butter maker required sanitary measurement solution

CCEP's reverse vending machine rollout

Bottle-filling physics: keeping it calm to prevent sloshing